Free Trial

Shattuck Labs (STTK) Competitors

Shattuck Labs logo
$0.82 +0.04 (+5.32%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$0.82 +0.01 (+0.67%)
As of 07/11/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

STTK vs. NVCT, CGEN, ACRS, BIOA, MOLN, ALEC, VTYX, LXEO, THTX, and BDTX

Should you be buying Shattuck Labs stock or one of its competitors? The main competitors of Shattuck Labs include Nuvectis Pharma (NVCT), Compugen (CGEN), Aclaris Therapeutics (ACRS), BioAge Labs (BIOA), Molecular Partners (MOLN), Alector (ALEC), Ventyx Biosciences (VTYX), Lexeo Therapeutics (LXEO), Theratechnologies (THTX), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry.

Shattuck Labs vs. Its Competitors

Nuvectis Pharma (NASDAQ:NVCT) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

In the previous week, Nuvectis Pharma had 3 more articles in the media than Shattuck Labs. MarketBeat recorded 4 mentions for Nuvectis Pharma and 1 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.89 beat Nuvectis Pharma's score of 1.85 indicating that Shattuck Labs is being referred to more favorably in the news media.

Company Overall Sentiment
Nuvectis Pharma Very Positive
Shattuck Labs Very Positive

Shattuck Labs' return on equity of -79.69% beat Nuvectis Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Nuvectis PharmaN/A -148.83% -95.60%
Shattuck Labs N/A -79.69%-69.13%

Nuvectis Pharma has higher earnings, but lower revenue than Shattuck Labs. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvectis PharmaN/AN/A-$19M-$1.13-6.97
Shattuck Labs$5.72M6.83-$75.41M-$1.39-0.59

Nuvectis Pharma currently has a consensus target price of $17.00, suggesting a potential upside of 115.74%. Shattuck Labs has a consensus target price of $7.50, suggesting a potential upside of 819.68%. Given Shattuck Labs' higher possible upside, analysts plainly believe Shattuck Labs is more favorable than Nuvectis Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvectis Pharma
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Shattuck Labs
0 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
2.83

96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 30.5% of Nuvectis Pharma shares are owned by company insiders. Comparatively, 12.0% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Nuvectis Pharma has a beta of -0.25, indicating that its share price is 125% less volatile than the S&P 500. Comparatively, Shattuck Labs has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500.

Summary

Shattuck Labs beats Nuvectis Pharma on 8 of the 15 factors compared between the two stocks.

Get Shattuck Labs News Delivered to You Automatically

Sign up to receive the latest news and ratings for STTK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STTK vs. The Competition

MetricShattuck LabsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$37.09M$2.97B$5.62B$9.10B
Dividend YieldN/A2.39%5.24%4.00%
P/E Ratio-0.5920.5828.0520.27
Price / Sales6.83292.05429.5999.27
Price / CashN/A42.8637.4658.16
Price / Book0.497.638.055.49
Net Income-$75.41M-$55.05M$3.18B$250.45M
7 Day Performance-2.34%8.43%3.60%4.77%
1 Month Performance-23.79%5.42%4.03%7.66%
1 Year Performance-80.54%2.03%29.49%16.39%

Shattuck Labs Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STTK
Shattuck Labs
3.718 of 5 stars
$0.82
+5.3%
$7.50
+819.7%
-79.9%$37.09M$5.72M-0.59100Positive News
High Trading Volume
NVCT
Nuvectis Pharma
3.365 of 5 stars
$7.85
+4.1%
$17.00
+116.6%
+23.1%$157.54MN/A-6.958
CGEN
Compugen
1.7847 of 5 stars
$1.72
-2.3%
$4.00
+132.6%
-9.1%$157.06M$27.86M-10.7570Gap Up
ACRS
Aclaris Therapeutics
2.2344 of 5 stars
$1.46
+1.4%
$9.71
+565.4%
+24.6%$155.93M$18.72M-1.05100Analyst Forecast
Gap Up
BIOA
BioAge Labs
N/A$4.18
-2.3%
N/AN/A$153.44MN/A0.00N/A
MOLN
Molecular Partners
3.1272 of 5 stars
$3.61
-4.0%
$12.00
+232.4%
-47.1%$151.81M$2.23M-1.88180
ALEC
Alector
3.9984 of 5 stars
$1.44
-4.6%
$4.00
+177.8%
-70.2%$150.99M$100.56M-1.14270News Coverage
VTYX
Ventyx Biosciences
3.5339 of 5 stars
$2.04
-1.9%
$10.00
+390.2%
+10.9%$148.01MN/A-1.1730News Coverage
Positive News
LXEO
Lexeo Therapeutics
2.3536 of 5 stars
$4.54
+2.0%
$16.60
+265.6%
-74.4%$147.73M$650K-1.3858Gap Up
High Trading Volume
THTX
Theratechnologies
N/A$3.17
-0.9%
N/A+117.2%$147.14M$85.87M-39.63140Earnings Report
High Trading Volume
BDTX
Black Diamond Therapeutics
2.7737 of 5 stars
$2.50
-3.1%
$12.80
+412.0%
-46.8%$146.71MN/A41.6790News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:STTK) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners